**Supplementary Table S1.** Definitions of outcomes in the UK Biobank cohort.

|  |  |
| --- | --- |
| **Outcome** | **Description of outcome\*** |
| **Pneumonia** | Viral pneumonia, not elsewhere classified |
|  | Pneumonia due to streptococcus pneumoniae |
|  | Pneumonia due to haemophilus influenzae |
|  | Bacterial pneumonia, not elsewhere classified |
|  | Pneumonia due to other infectious organisms, not elsewhere classified |
|  | Pneumonia in diseases classified elsewhere |
|  | Pneumonia, organism unspecified |
| **Influenza** | Influenza due to certain identified influenza virus |
|  | Influenza due to identified influenza virus |
|  | Influenza, virus not identified |
| **COVID-19 infection** | Positive COVID test, and included patients with in-patient COVID diagnosis and cause of death due to COVID-19 |
| **COVID-19 severity** | In-patient diagnosis of COVID-19 |
| **COVID-19 mortality** | Underlying (primary) cause of death due to COVID-19 |
| **Other upper respiratory infections** | Acute nasopharyngitis (common cold) |
|  | Acute sinusitis |
|  | Acute pharyngitis |
|  | Acute tonsillitis |
|  | Acute laryngitis and tracheitis |
|  | Acute obstructive laryngitis (croup) and epiglottitis |
|  | Acute upper respiratory infections of multiple and unspecified sites |
| **Other lower respiratory infections** | Acute bronchitis |
|  | Acute bronchiolitis |
|  | Unspecified acute lower respiratory infection |

\*First reported date was used for the outcome.

**Supplementary Table S2.** Associations of PPI use with COVID-19 severity and mortality.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Case/person-years** | **Non-adjusted model** | **Age/sex-adjusted model** | **Fully adjusted model\*** |
|  | **HR (95% CI)** | ***P*** | **HR (95% CI)** | ***P*** | **HR (95% CI)** | ***P*** |
| **COVID-19 severity** |  |  |  |  |  |  |  |
| **Non-regular PPI use** | 766/8 951 | 1.00 (reference) |  | 1.00 (reference) |  | 1.00 (reference) |  |
| **Regular PPI use** | 88/1 026 | 2.03 (1.63-2.54) | **<0.001** | 1.72 (1.38-2.14) | **<0.001** | 1.27 (0.99-1.62) | 0.055 |
| **COVID-19 mortality** |  |  |  |  |  |  |  |
| **Non-regular PPI use** | 2 725/32 494 | 1.00 (reference) |  | 1.00 (reference) |  | 1.00 (reference) |  |
| **Regular PPI use** | 314/3 774 | 1.36 (1.21-1.53) | **<0.001** | 1.03 (0.92-1.16) | 0.598 | 1.02 (0.90-1.12) | 0.785 |

\*Adjusted for age, sex, ethnicity, deprivation index, smoking, alcohol consumption, physical activity, fresh fruit intake, body mass index, any indication of PPIs (gastroesophageal reflux disease [GERD], peptic ulcer, upper gastrointestinal bleeding), comorbidities (hypertension, type 2 diabetes, renal failure, myocardial infarction, stroke, chronic obstructive pulmonary disease [COPD], asthma), medications (aspirin, non-aspirin non-steroidal anti-inflammatory drugs [NSAIDs, ibuprofen], histamine 2 receptor antagonists (H2RAs), cholesterol lowering medications), and multivitamin use.

CI: confidence interval; COVID-19: coronavirus disease 2019;HR: hazard ratio; PPI: proton pump inhibitor.

**Supplementary Table S3.** Associations of PPI use with the risk of pneumonia, influenza, COVID-19, and other respiratory infections by different types of PPIs.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Case/Person-years** | **HR (95% Cl)\*** | ***P*** |
| **Pneumonia** |  |  |  |
| Non-regular PPI use | 2 904/12 867 | 1.00 (Reference) |  |
| Omeprazole | 4 193/30 701 | 1.49 (1.29-1.74) | **<0.001** |
| Lansoprazole | 2 459/17 382 | 1.54 (1.27-1.86) | **<0.001** |
| Esomeprazole | 233/1 730 | 1.66 (0.96-2.88) | 0.069 |
| Rabeprazole | 118/868 | 1.10 (0.46-2.66) | 0.827 |
| Pantoprazole | 143/1 070 | 1.58 (0.78-3.17) | 0.201 |
| **Influenza** |  |  |  |
| Non-regular PPI use | 2 009/6 011 | 1.00 (Reference) |  |
| Omeprazole | 96/306 | 1.38 (1.11-1.71) | **0.004** |
| Lansoprazole | 33/75 | 0.85 (0.60-1.22) | 0.384 |
| Esomeprazole | 1/1 | 0.26 (0.04-1.86) | 0.180 |
| Rabeprazole | 1/1 | 0.57 (0.08-4.04) | 0.572 |
| Pantoprazole | 3/3 | 1.26 (0.40-3.93) | 0.690 |
| **Other upper respiratory infection** |  |  |  |
| Non-regular PPI use | 14 449/52 499 | 1.00 (Reference) |  |
| Omeprazole | 534/1 959 | 1.14 (1.04-1.25) | **0.006** |
| Lansoprazole | 411/1 085 | 1.18 (1.05-1.33) | **0.006** |
| Esomeprazole | 28/95 | 1.17 (0.81-1.70) | 0.408 |
| Rabeprazole | 9/38 | 0.65 (0.34-1.25) | 0.193 |
| Pantoprazole | 21/74 | 1.41 (0.92-2.16) | 0.119 |
| **Other lower respiratory infection** |  |  |  |
| Non-regular PPI use | 14 494/55 384 | 1.00 (Reference) |  |
| Omeprazole | 705/2 723 | 1.31 (1.21,1.42) | **<0.001** |
| Lansoprazole | 397/1 424 | 1.30 (1.17,1.44) | **<0.001** |
| Esomeprazole | 39/148 | 1.35 (0.98,1.85) | 0.066 |
| Rabeprazole | 16/67 | 0.94 (0.58,1.54) | 0.813 |
| Pantoprazole | 23/107 | 1.23 (0.82,1.86) | 0.317 |
| **COVID-19 positivity**  |  |  |  |
| Non-regular PPI use | 6 443/77 867 | 1.00 (Reference) |  |
| Omeprazole | 258/3 111 | 0.99 (0.87-1.13) | 0.918 |
| Lansoprazole | 142/1 705 | 1.19 (1.00-1.41) | **0.048** |
| Esomeprazole | 15/183 | 0.94 (0.56-1.57) | 0.810 |
| Rabeprazole | 7/87 | 1.56 (0.74-3.28) | 0.242 |
| Pantoprazole | 5/60 | 0.90 (0.38-2.17) | 0.820 |
| **COVID-19 severity** |  |  |  |
| Non-regular PPI use | 2 952/36 421 | 1.00 (Reference) |  |
| Omeprazole | 64/796 | 1.25 (0.90-1.74) | 0.190 |
| Lansoprazole | 43/538 | 1.31 (0.86.1.97) | 0.205 |
| Esomeprazole | - | - | - |
| Rabeprazole | 1/12 | 2.98 (1.06-8.33) | 0.038 |
| Pantoprazole | - | - | - |
| **COVID-19 mortality** |  |  |  |
| Non-regular PPI use | 2 725/32 494 | 1.00 (Reference) |  |
| Omeprazole | 152/1 834 | 0.95 (0.80-1.13) | 0.596 |
| Lansoprazole | 72/851 | 1.00 (0.78-1.27) | 0.975 |
| Esomeprazole | 10/122 | 1.32 (0.71-2.46) | 0.388 |
| Rabeprazole | 2/25 | 0.63 (0.16-2.54) | 0.517 |
| Pantoprazole | 4/48 | 1.64 (0.61-4.40) | 0.329 |

CI: confidence interval; COVID-19: coronavirus disease 2019;HR: hazard ratio; PPI: proton pump inhibitor.

\*Fully adjusted model

**Supplementary Table S4.** Associations of PPI use with COVID-19 severity and mortality by *CYP2C19* phenotypes

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Case/Person-years** | **HR (95% Cl)** | ***P*** | ***Pi*** |
| **COVID-19 severity** |  |  |  | 0.184 |
| Non-regular PPI user | 2 952/36 421 | 1.00 (reference) |  |  |
| PPI user, *CYP2C19* Rapid and ultrarapid metabolizers | 62/765 | 1.10 (0.75-1.62) | 0.616 |  |
| PPI user, *CYP2C19* normal metabolizers | 60/745 | 1.44 (1.06-1.95) | **0.019** |  |
| PPI user, *CYP2C19* likely intermediate, intermediate and poor metabolizers | - | - | - |  |
| **COVID-19 mortality** |  |  |  | 0.643 |
| Non-regular PPI user | 2725/32 494 | 1.00 (reference) |  |  |
| PPI user, *CYP2C19* Rapid and ultrarapid metabolizers | 135/1 609 | 1.05 (0.97-1.26) | 0.602 |  |
| PPI user, *CYP2C19* normal metabolizers | 145/1 750 | 1.00 (0.83-1.19) | 0.959 |  |
| PPI user, *CYP2C19* likely intermediate, intermediate and poor metabolizers | 8/99 | 0.76 (0.38-1.54) | 0.450 |  |

CI: confidence interval; COVID-19: coronavirus disease 2019;HR: hazard ratio; *P* for interaction among different types of metabolizers; PPI: proton pump inhibitor.

**Supplementary Table S5.** Clinical characteristics of included participants after propensity score-matching

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Regular PPI** **user** | **Matched PPI** **non-user** | **Overall** | **Standardized mean difference** |
| **Number of participants, n (%)** | 9 940 (20%) | 39 760 (80%) | 49 700 (100%) |  |
| **Age, years, mean (SD)** | 59.4 (7.4) | 60.2 (7.0) | 60.1 (7.1) | **-0.11** |
| **Sex, female, n (%)** | 5 498 (55.3) | 22 400 (56.3) | 27 898 (56.1) | 0.02 |
| **Ethnicity, white, n (%)** | 9 518 (95.8) | 37 973 (95.5) | 47 491 (95.6) | 0.01 |
| **Deprivation index, mean (SD)** | -0.92 (3.3) | -0.76 (3.23) | -0.79 (3.24) | -0.05 |
| **Alcohol consumption, n (%)** |  |  |  | 0.06 |
| **Daily or almost daily** | 1 793 (18.0) | 6 985 (17.6) | 8 778 (17.7) |  |
| **3 or 4 times a week** | 1 913 (19.2) | 7 123 (17.9) | 9 036 (18.2) |  |
| **1 or 2 times a week** | 2 384 (24.0) | 9 182 (23.1) | 11 566 (23.3) |  |
| **1 to 3 times a month** | 1 173 (11.8) | 4 750 (11.9) | 5 923 (11.9) |  |
| **Special occasions only** | 1 510 (15.2) | 6 524 (16.4) | 8 034 (16.2) |  |
| **Never** | 1 156 (11.6) | 5 138 (12.9) | 6 294 (12.7) |  |
| **Smoking, n (%)** |  |  |  | 0.04 |
| **Never smoker** | 4 545 (45.7) | 17 368 (43.7) | 21 913 (44.1) |  |
| **Previous smoker** | 4 263 (42.9) | 17 754 (44.7) | 22 017 (44.3) |  |
| **Current smoker** | 1 132 (11.4) | 4 638 (11.7) | 5 770 (11.6) |  |
| **Physical activity, MET minutes/week, median (IQR)** | 1 527 (2 721.0) | 1 533 (2 494.5) | 1 530 (2 548.0) | 0.03 |
| **Fresh fruit intake, pieces, mean (SD)** | 2.0 (2.6) | 2.0 (2.6) | 2.0 (2.6) | 0.02 |
| **BMI, kg/m2, mean (SD)** | 29.2 (5.1) | 29.7 (5.6) | 29.6 (5.5) | 0.09 |
| **Indication of PPIs, n (%)** |  |  |  |  |
| **GERD** | 3 215 (32.3) | 3 996 (10.1) | 7211 (14.5) | **0.48** |
| **Peptic ulcer** | 554 (5.6) | 1 282 (3.2) | 1836 (3.7) | **0.10** |
| **Upper gastrointestinal bleeding**  | 18 (0.2) | 38 (0.1) | 56 (0.1) | 0.02 |
| **Comorbidities, n (%)** |  |  |  |  |
| **Hypertension** | 4 083 (41.1) | 18 933 (47.6) | 23016 (46.3) | 0.13 |
| **Type 2 diabetes** | 124 (1.2) | 598 (1.5) | 722 (1.5) | 0.02 |
| **Renal failure** | 60 (0.6) | 216 (0.5) | 276 (0.6) | 0.01 |
| **Myocardial infarction**  | 326 (3.3) | 1 472 (3.7) | 1798 (3.6) | 0.02 |
| **Stoke** | 135 (1.4) | 659 (1.7) | 794 (1.6) | 0.02 |
| **COPD**  | 45 (0.5) | 175 (0.4) | 220 (0.4) | 0.001 |
| **Asthma**  | 834 (8.4) | 3 489 (8.8) | 4 323 (8.7) | 0.01 |
| **Medication use, n (%)** |  |  |  |  |
| **Aspirin**  | 2 429 (24.4) | 11 898 (29.9) | 14 327 (28.8) | **0.13** |
| **Non-aspirin NSAIDS** | 1 205(12.1) | 4 734 (11.9) | 5 939 (11.9) | 0.01 |
| **H2RA** | 295 (3.0) | 1 182 (3.0) | 1 477 (3.0) | 0.0003 |
| **Cholesterol lowering medication** | 1 526(15.4) | 7 311 (18.4) | 8 837 (17.8) | 0.08 |
| **Multivitamin use, n (%)** | 2 213(22.3) | 8 979 (22.6) | 11 192 (22.5) | 0.01 |

BMI: body mass index; COPD: chronic obstructive pulmonary disease;GERD: gastroesophageal reflux disease; H2RA: histamine 2 receptor antagonist; IQR: interquartile range; MET: metabolic equivalent of task; PPI: proton pump inhibitor; NSAIDS: non-steroidal anti-inflammatory drugs; SD: standard deviation.

**Supplementary Table S6.** Propensity score-matched analysis of associations of PPI use with the risk of pneumonia, influenza, COVID-19, and other respiratory infections

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Cases / Person-years** | **Unadjusted****HR (95%CI)** | ***P*** | **Multivariable-adjusted model\*** | ***P*** |
| **Pneumonia** |  |  |  |  |  |
| **Non-regular PPI use** | 1 263/5 688 | 1.00 (Reference) |  | 1.00 (Reference) |  |
| **Regular PPI use** | 377/1 699 | 1.20 (1.07-1.35) | **0.001** | 1.33 (1.18-1.50) | **<0.001** |
| **Influenza**  |  |  |  |  |  |
| **Non-regular PPI use** | 560/1 582 | 1.00 (Reference) |  | 1.00 (Reference) |  |
| **Regular PPI use** | 183/539 | 1.31 (1.11-1.55) | **0.001** | 1.33 (1.12-1.58) | **0.001** |
| **COVID-19** |  |  |  |  |  |
| **Non-regular PPI use** | 2 065/24 763 | 1.00 (Reference) |  | 1.00 (Reference) |  |
| **Regular PPI use** | 533/6 423 | 0.96 (0.86-1.06) | 0.433 | 1.01 (0.92-1.12) | 0.789 |
| **Other upper respiratory infection** |  |  |  |  |  |
| **Non-regular PPI use** | 4 028/14 496 | 1.00 (Reference) |  | 1.00 (Reference) |  |
| **Regular PPI use** | 1 111/3 964 | 1.20 (1.12-1.28) | **<0.001** | 1.18 (1.10-1.26) | **<0.001** |
| **Other lower respiratory infection** |  |  |  |  |  |
| **Non-regular PPI use** | 4 849/18 589 | 1.00 (Reference) |  | 1.00 (Reference) |  |
| **Regular PPI use** | 1 475/5 549 | 1.30 (1.22-1.37) | **<0.001** | 1.33 (1.26-1.42) | **<0.001** |

\*Adjusted for age, gastroesophageal reflux disease, peptic ulcer, and aspirin use.

CI: confidence interval; COVID-19: coronavirus disease 2019;HR: hazard ratio; PPI: proton pump inhibitor.

**Supplementary Table S7.** Propensity score-matched analysis of associations of PPI use with COVID-19 severity and mortality.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Cases / Person-years** | **Unadjusted****HR (95%CI)** | ***P*** | **Multivariable-adjusted model\*** | ***P*** |
| **COVID-19 severity** |  |  |  |  |  |
| **Non-regular PPI use** | 318/3 715 | 1.00 (Reference) |  | 1.00 (Reference) |  |
| **Regular PPI use** | 88/1 026 | 1.07 (0.84-1.35) | 0.585 | 1.18 (0.93-1.51) | 0.180 |
| **COVID-19 mortality** |  |  |  |  |  |
| **Non-regular PPI use** | 1 203/14 345 | 1.00 (Reference) |  | 1.00 (Reference) |  |
| **Regular PPI use** | 314/3 774 | 0.92 (0.81-1.04) | 0.199 | 0.98 (0.86-1.12) | 0.792 |

\*Adjusted for age, gastroesophageal reflux disease, peptic ulcer, and aspirin use.

CI: confidence interval; COVID-19: coronavirus disease 2019;HR: hazard ratio; PPI: proton pump inhibitor.